Upcoming Issue Highlights
Home Subscribe Advertise Sourcebook Free Product Info Home

Open Book Extracts Completes Phase 1 of Toxicology and Safety Assessment for CBG, CBN and CBC


Open Book Extracts (OBX, Roxboro, NC) has announced the completion of phase one of the toxicology and safety results for its Open-Book-Extractscannabinoid ingredients cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC). OBX contracted respected scientific and regulatory consulting firm, AIBMR Life Sciences, Inc, to conduct the battery of toxicological studies to investigate the safety of the consumption of its CBG, CBN and CBC that will support a generally recognized as safe (GRAS) independent conclusion or new dietary ingredient (NDI) application.

Non-GMO Project

The report concluded that the test articles were non-mutagenic, non-clastogenic and non-genotoxic. The toxicological assessment is the first known published data of its kind since the 1980 Rosenkrantz et al. ‘s publication with respect to toxicology data on CBD, Cannabichromene and hashish oil. The battery of GLP/OECD compliant studies is a major contribution in the advancement of the science of hemp-derived CBD.

The investment in this toxicological assessment demonstrates OBX’s commitment in furthering the science behind cannabinoid ingredients.

“Until today, there have been no comprehensive toxicological safety assessments completed on minor cannabinoids, including CBG, CBN and CBC,” said Chelsea Pipkin, OBX vice president of quality assurance. “The completion and publication of these safety studies on these ingredients in a peer-reviewed academic journal specializing in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”

Dave Neundorfer, OBX chief executive officer added, “We are thrilled to advance cannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS or NDI status. As an organization, our commitment to safety remains paramount. We look forward to setting the bar for all cannabinoid manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”

For more information, visit https://openbookextracts.com/.